GlassScriptPhysician profile
James G Sigmon
NPI 1356408207
$16,266.74
in general payments reported to CMS, 2019-2025
35 companies · $1,337 in 2025
The $1,337 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,971 · 2020: $2,119 · 2021: $2,732 · 2022: $2,813 · 2023: $2,417 · 2024: $1,878 · 2025: $1,337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,632.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,632.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,573.68 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $2,327.44 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $1,729.06 | 2019-2025 | Otezla, Repatha, Otezla |
| Lilly USA, LLC | $1,403.93 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $1,146.23 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $1,113.87 | 2021-2025 | |
| Esperion Therapeutics, INC. | $800.87 | 2020-2025 | Nexletol, Nexlizet |
| Boehringer Ingelheim Pharmaceuticals, INC. | $754.38 | 2019-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $699.61 | 2019-2025 | Verquvo, Gardasil 9, Capvaxive |
| Sanofi-Aventis U.S. LLC | $576.91 | 2019-2024 | |
| Amarin Pharma, INC. | $330.39 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $291.16 | 2020-2023 | |
| Pfizer INC. | $237.37 | 2020-2023 | |
| Kowa Pharmaceuticals America, INC. | $173.72 | 2019-2023 | Livalo |
| Glaxosmithkline, LLC. | $158.48 | 2019-2024 | Arexvy, Trelegy Ellipta |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $127.11 | 2019 | |
| Ironshore Pharmaceuticals INC. | $119.20 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $117.67 | 2019-2021 | |
| Harmony Biosciences LLC | $115.18 | 2023 | Wakix |
| Abbvie INC. | $104.07 | 2019-2022 | |
| Exact Sciences Corporation | $75.63 | 2023-2024 | Cologuard Collection Kit |
| Abbott Laboratories | $51.88 | 2022-2023 | Freestyle Libre 2 |
| Sunovion Pharmaceuticals INC. | $45.59 | 2021-2022 | |
| Shire North American Group INC | $25.49 | 2019 | |
| Corium, LLC | $18.08 | 2022 | |
| Mylan Specialty L.P. | $16.96 | 2020 | |
| Eisai INC. | $16.86 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $16.62 | 2022 | |
| Corcept Therapeutics | $16.28 | 2024 | Korlym |
| Janssen Scientific Affairs, LLC | $15.56 | 2019 | |
| Hikma Pharmaceuticals USA | $15.14 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.61 | 2021 | |
| Bausch Health US, LLC | $14.30 | 2019 | |
| Biogen, INC. | $11.92 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Sigmon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.